0001209191-23-004223.txt : 20230120 0001209191-23-004223.hdr.sgml : 20230120 20230120160536 ACCESSION NUMBER: 0001209191-23-004223 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230119 FILED AS OF DATE: 20230120 DATE AS OF CHANGE: 20230120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Jason CENTRAL INDEX KEY: 0001741553 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 23540999 MAIL ADDRESS: STREET 1: C/O ALBIREO PHARMA, INC. STREET 2: 10 POST OFFICE SQUARE, SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 10 POST OFFICE SQUARE STREET 2: SUITE 502 SOUTH CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-19 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001741553 Duncan Jason C/O ALBIREO PHARMA, INC. 53 STATE STREET, 19TH FLOOR BOSTON MA 02109 0 1 0 0 Chief Legal Officer and GC Common Stock 2023-01-19 4 S 0 938 43.9044 D 14374 D Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Represents 2,867 shares of common stock and 11,507 restricted stock units. Includes 381 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on November 30, 2022. /s/ Jason Duncan 2023-01-20